Advert - Moderna – Case AUTH/3783/6/23

For paying a UK health professional to attend a meeting that did not meet the criteria for a genuine advisory board and therefore paying a fee to attend, in effect, a promotional meeting that detailed an investigational product which at the time did not have a marketing authorisation and an indication for a medicine that was inconsistent with its summary of product characteristics, Moderna was ruled in breach of the following clauses of the 2021 Code:

 

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1 - Failing to maintain high standards

Clause 11.1 - Promoting a medicine prior to the grant of its marketing authorisation

Clause 11.2 - Promoting a medicine in a manner inconsistent with its summary of product characteristics

Clause 19.1 - Provision of a pecuniary advantage or benefit to a health professional in connection with the promotion of medicines or as an inducement to prescribe, supply, administer and/or recommend a medicine

Advert February 2025